Literature DB >> 21810750

Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa.

Karen R Jacobson1, Danie Theron, Thomas C Victor, Elizabeth M Streicher, Robin M Warren, Megan B Murray.   

Abstract

We report treatment outcomes from a retrospective cohort of patients with isoniazid-monoresistant tuberculosis in rural South Africa. Sixteen percent of patients had poor outcomes, 61% of whom progressed to multidrug-resistant tuberculosis. These data reveal the need for early identification and aggressive follow-up of isoniazid monoresistance to increase treatment success.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21810750      PMCID： PMC3202325          DOI： 10.1093/cid/cir406

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  Programmes and principles in treatment of multidrug-resistant tuberculosis.

Authors:  Joia S Mukherjee; Michael L Rich; Adrienne R Socci; J Keith Joseph; Felix Alcántara Virú; Sonya S Shin; Jennifer J Furin; Mercedes C Becerra; Donna J Barry; Jim Yong Kim; Jaime Bayona; Paul Farmer; Mary C Smith Fawzi; Kwonjune J Seung
Journal:  Lancet       Date:  2004-02-07       Impact factor: 79.321

2.  Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome.

Authors:  Didi Bang; Peter Henrik Andersen; Ase Bengaard Andersen; Vibeke Østergaard Thomsen
Journal:  J Infect       Date:  2010-03-27       Impact factor: 6.072

3.  Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study.

Authors:  Keertan Dheda; Karen Shean; Alimuddin Zumla; Motasim Badri; Elizabeth M Streicher; Liesl Page-Shipp; Paul Willcox; Melanie-Anne John; Gary Reubenson; Darshini Govindasamy; Michelle Wong; Xavier Padanilam; Alicia Dziwiecki; Paul D van Helden; Sweetness Siwendu; Julie Jarand; Colin N Menezes; Avril Burns; Thomas Victor; Robin Warren; Martin P Grobusch; Martie van der Walt; Charlotte Kvasnovsky
Journal:  Lancet       Date:  2010-05-22       Impact factor: 79.321

4.  Timing of initiation of antiretroviral drugs during tuberculosis therapy.

Authors:  Salim S Abdool Karim; Kogieleum Naidoo; Anneke Grobler; Nesri Padayatchi; Cheryl Baxter; Andrew Gray; Tanuja Gengiah; Gonasagrie Nair; Sheila Bamber; Aarthi Singh; Munira Khan; Jacqueline Pienaar; Wafaa El-Sadr; Gerald Friedland; Quarraisha Abdool Karim
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

5.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

6.  Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.

Authors:  Adithya Cattamanchi; Raymund B Dantes; John Z Metcalfe; Leah G Jarlsberg; Jennifer Grinsdale; L Masae Kawamura; Dennis Osmond; Philip C Hopewell; Payam Nahid
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

7.  The clinical relevance of Mycobacterial pharmacogenetics.

Authors:  R M Warren; E M Streicher; N C Gey van Pittius; B J Marais; G D van der Spuy; T C Victor; F Sirgel; P R Donald; P D van Helden
Journal:  Tuberculosis (Edinb)       Date:  2009-05-01       Impact factor: 3.131

8.  High-resolution CT findings in patients with pulmonary tuberculosis: correlation with the degree of smear positivity.

Authors:  Fatih Ors; Omer Deniz; Ugur Bozlar; Seyfettin Gumus; Mustafa Tasar; Ergun Tozkoparan; Cem Tayfun; Hayati Bilgic; Brydon J B Grant
Journal:  J Thorac Imaging       Date:  2007-05       Impact factor: 3.000

Review 9.  Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt
Journal:  PLoS Med       Date:  2009-09       Impact factor: 11.069
  9 in total
  41 in total

1.  Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs.

Authors:  Sophia B Georghiou; Marva Seifert; Donald G Catanzaro; Richard S Garfein; Timothy C Rodwell
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

2.  7th Union Europe Conference on Lung Health, 22-24 June 2016, Bratislava (Slovakia): a delegate report.

Authors:  Aliaksandr Skrahin
Journal:  Quant Imaging Med Surg       Date:  2016-08

3.  Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis.

Authors:  Jimena Collantes; Francesca Barletta Solari; Leen Rigouts
Journal:  Am J Trop Med Hyg       Date:  2016-10-24       Impact factor: 2.345

4.  Rapid detection of isoniazid resistance in Mycobacterium tuberculosis isolates by use of real-time-PCR-based melting curve analysis.

Authors:  Siyu Hu; Guoli Li; Hui Li; Xiaoli Liu; Jianjun Niu; Shengmao Quan; Feng Wang; Huixin Wen; Ye Xu; Qingge Li
Journal:  J Clin Microbiol       Date:  2014-03-05       Impact factor: 5.948

5.  Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.

Authors:  Y F van der Heijden; F Karim; G Mufamadi; L Zako; T Chinappa; B E Shepherd; F Maruri; M-Y S Moosa; T R Sterling; A S Pym
Journal:  Int J Tuberc Lung Dis       Date:  2017-06-01       Impact factor: 2.373

6.  Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti.

Authors:  Kathleen F Walsh; Stalz Charles Vilbrun; Ariadne Souroutzidis; Sobieskye Delva; Guy Joissaint; Laurent Mathurin; Oksana Ocheretina; Pierre Cremieux; Jean William Pape; Serena P Koenig
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

Review 7.  Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren
Journal:  Lancet Respir Med       Date:  2014-03-24       Impact factor: 30.700

8.  The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity.

Authors:  E S Click; J Chirenda; S Kibias; H J Menzies; J E Oeltmann; C Sentle; T Muribe; T D Lere; R Makombe; S Bamrah; B K Moore; K P Cain
Journal:  Int J Tuberc Lung Dis       Date:  2014-11       Impact factor: 2.373

9.  Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.

Authors:  Anne F Luetkemeyer; Michelle A Kendall; Xingye Wu; Maria Cristina Lourenço; Ute Jentsch; Susan Swindells; Sarojini S Qasba; Jorge Sanchez; Diane V Havlir; Beatriz Grinsztejn; Ian M Sanne; Cynthia Firnhaber
Journal:  J Clin Microbiol       Date:  2014-01-15       Impact factor: 5.948

10.  First Evaluation of GenoType MTBDRplus 2.0 Performed Directly on Respiratory Specimens in Central America.

Authors:  Fedora Lanzas; Thomas R Ioerger; Harita Shah; William Acosta; Petros C Karakousis
Journal:  J Clin Microbiol       Date:  2016-07-20       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.